dr. mesa on the efficacy of fedratinib in patients with myelofibrosis and low platelet counts
Published 4 years ago • 132 plays • Length 2:13Download video MP4
Download video MP3
Similar videos
-
1:11
dr. mesa on the utility of fedratinib for patients with myelofibrosis who progress on ruxolitinib
-
1:00
dr. mesa on the utility of ruxolitinib versus fedratinib in myelofibrosis
-
1:24
dr. mesa on current data with ruxolitinib and fedratinib in myelofibrosis
-
1:29
dr. mesa on the fda approval of fedratinib in myelofibrosis
-
1:16
dr. mesa on the fda approval of fedratinib in myelofibrosis
-
0:55
dr. mesa on intended patients with myelofibrosis for pacritnib
-
1:39
is fedratinib a safe and efficacious treatment option for patients with pmf and low platelet counts?
-
22:26
what's your approach? treating myelofibrosis
-
1:42
dr. mesa on ruxolitinib vs fedratinib in myelofibrosis treatment
-
1:12
dr. mesa on the differences between fedratinib and ruxolitinib in myelofibrosis
-
0:57
dr. mesa on challenges in myelofibrosis treatment
-
7:43
the role of fedratinib in myelofibrosis
-
1:48
dr. mesa on pacritinib for myelofibrosis
-
1:12
dr. kuykendall on the approval of fedratinib in myelofibrosis
-
1:42
momelotinib vs. ruxolitinib in myelofibrosis patients with thrombocytopenia
-
5:10
fedratinib in mf: jakarta2 and freedom trials
-
1:27
real-world use of fedratinib in patients with mf who have failed on ruxolitinib
-
30:30
dr ruben mesa-myelofibrosis and advancing mpns: current and future approaches
-
0:56
dr. saint fleur-lominy on the use of ruxolitinib versus fedratinib in mpns